Imatinib plus Cetuximab as a Window of Opportunity Clinical Trial in Head and Neck Cancer
Cetuximab, an approved anti-EGFR receptor monoclonal antibody, is used for the treatment of metastatic cancer, often in conjunction with cytotoxic chemotherapy. It is also employed as a radiosensitizer in the context of definitive radiation therapy for locally advanced cases. However, overcoming resistance to cetuximab, whether intrinsic or acquired, represents a significant challenge in clinical practice. In preclinical studies, the identification of tyrosine 821 (Y821) on the C-terminal of AXL has been linked to resistance to both cetuximab and radiation therapy via signaling through the tyrosine kinase c-Abl.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: J.Y. Bruce, T. Glazer, M. Iida, B. Mehall, K.L. Kostecki, M. Yu, A. Wieland, G.K. Hartig, T.M. McCulloch, D. Trask, A. Burr, P.M. Harari, R.J. Kimple, D.L. Wheeler Tags: 223 Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Erbitux | Gleevec | Head and Neck Cancer | Physics | Radiation Therapy | Radiology | Study